Product Description
Dibekacin sulfate JP15 Pharmaceutical Antibiotics made in china 58580-55-5
AI Product Description
*The following content is generated by AI and is for reference only.
Dibekacin sulfate, recognized under the Japanese Pharmacopoeia 15th edition (JP15), is a potent semi-synthetic aminoglycoside antibiotic manufactured in China for global pharmaceutical distribution. Chemically known as dibekacin sulfate, its molecular formula is C20H43N5O13S and it carries the CAS Registry Number 68497-56-3. This compound serves as the sulfate salt of dibekacin, an aminoglycoside derived from the fermentation product of *Micromonospora* species, subsequently modified to enhance its antibacterial spectrum and stability against bacterial resistance mechanisms.
The primary therapeutic application of Dibekacin sulfate lies in the treatment of serious infections caused by susceptible Gram-negative bacteria. It is particularly effective against strains of *Pseudomonas aeruginosa*, *Escherichia coli*, *Klebsiella pneumoniae*, and *Proteus* species that exhibit resistance to other aminoglycosides like gentamicin or tobramycin. The drug functions by binding irreversibly to the 30S ribosomal subunit of bacteria, thereby inhibiting protein synthesis and leading to rapid bactericidal activity. Due to its specific chemical structure, it often retains efficacy against organisms producing certain modifying enzymes that inactivate other antibiotics in its class.
In clinical practice, Dibekacin sulfate is typically administered via intramuscular injection or intravenous infusion, with dosing carefully calculated based on patient weight, renal function, and serum concentration monitoring to minimize toxicity. While generally well-tolerated when used correctly, potential adverse effects include nephrotoxicity and ototoxicity, necessitating strict medical supervision. As a high-quality API produced in China, it meets rigorous international standards outlined in JP15, ensuring purity, potency, and safety for use in treating severe hospital-acquired infections, sepsis, and complicated urinary tract infections. Its availability supports critical care needs where broad-spectrum coverage against multidrug-resistant pathogens is essential, making it a valuable component in modern antimicrobial stewardship programs worldwide.